ESMO 2024 丨 Dr. Jennifer Chan: The CABINET trial adds a major new treatment “weapon” for patients with advanced neuroendocrine tumors

ESMO 2024 丨 Dr. Jennifer Chan: The CABINET trial adds a major new treatment “weapon” for patients with advanced neuroendocrine tumors

2024.10.14
The CABINET study (abstract number 11410), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), updated the latest results of cabozantinib versus placebo in the treatment of advanced neuroendocrine tumors (NETs) after progression following previous treatment. At the conference site, we specially invited the Principal Investigator, Dr. Jennifer Chan from the Dana-Farber Cancer Institute in Boston, to be interviewed by us on site.
Dr. Lorenza Rimassa: The 5-year OS update of the HIMALAYA study sets a new high for survival in first-line treatment of advanced liver cancer

Dr. Lorenza Rimassa: The 5-year OS update of the HIMALAYA study sets a new high for survival in first-line treatment of advanced liver cancer

2024.10.14
Immunotherapy for advanced liver cancer has advanced rapidly and has become a standard first-line treatment. A HIMALAYA study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the new immunotherapy combination STRIDE—tremelimumab and durvalumab compared with sorafenib. Dr. Lorenza Rimassa, the Principal Investigator from Humanitas University in Italy, was interviewed by us on site.
Interview with Dr. Michael Wang – Exciting Developments in Lymphoma Treatment! 

Interview with Dr. Michael Wang – Exciting Developments in Lymphoma Treatment! 

2024.10.14
In a recent Hematology Frontier interview, Dr. Michael Wang shared insights from the EHA Late Breaker Plenary Session, where the pivotal ECHO clinical trial was discussed. the study is leading to breakthroughs in lymphoma care. The promising combination of BR + Acalabrutinib shows potential to improve outcomes, especially for older patients. This could pave the way for better therapies globally!
New Advances in Renal Cancer Treatment

New Advances in Renal Cancer Treatment

2024.10.14
Excited to share this insightful talk with Dr. Liangyou Gu on tackling clear cell renal cell carcinoma with innovative approaches like neoadjuvant toripalimab. The future of kidney cancer treatment is evolving, and these advancements are offering real hope for better outcomes. Watch the video for key highlights!
Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive

Dr. Yelena Janjigian: The DESTINY-Gastric03 study confirms the therapeutic prospect of the T-DXd triple regimen in HER2-positive

2024.10.14
The DESTINY-Gastric03 study (abstract number 14010), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), evaluated the efficacy and safety of T-DXd combined with FP and anti-PD-1 as first-line treatment for adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJA). At the conference site, we specially invited the Principal Investigator, Dr. Yelena Janjigian from Memorial Sloan Kettering Cancer Center in the United States, to be interviewed by us on site.
Dr. Aiming Pang: The “Tianjin Model” of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

Dr. Aiming Pang: The “Tianjin Model” of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia

2024.10.13
Autologous hematopoietic stem cell transplantation (ASCT) is a treatment option for adult acute leukemia in remission. Compared to allogeneic hematopoietic stem cell transplantation (allo-HSCT), ASCT has advantages such as no donor restrictions, absence of graft-versus-host disease (GVHD), and a lower transplant-related mortality rate. At the recent "4th Shanghai Symposium on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation," Dr. Aimang Pang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, delivered an insightful presentation on the "Tianjin Model" for ASCT in treating acute leukemia. The highlights of the presentation are summarized here for our readers.
Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

Dr. He Huang and Didier Blaise: Exploring Breakthroughs in Cellular Therapy from Sino-French Perspectives

2024.10.13
The 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, recently took place in Tianjin, drawing hundreds of leading experts and scholars in the field of hematology from around the world. During the conference, Hematology Frontier invited Dr. He Huang from The First Affiliated Hospital, Zhejiang University School of Medicine and Dr. Didier Blaise from the Hematology Institute of Aix-Marseille University in France to engage in a dialogue on the challenges and opportunities in new cellular therapies for hematologic malignancies. Here are the key insights from their conversation.